- Trial Phase
- Preclinical
- Time to Market
- Preclinical stage only; no clinical trials have been initiated. If development proceeds, castanospermine would likely be years away from any potential regulatory filing, contingent on the company securing substantial additional financing.
- Why 2/10
- No hard, dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for castanospermine in the next ~12 months; the program is at preclinical/nonclinical stage. The company's near-term binary events (January 2027 tafenoquine babesiosis data) are unrelated to this drug.
Castanospermine is a preclinical-stage asset with no clinical trials planned or registered. The next meaningful catalyst would be any decision by 60 Degrees Pharmaceuticals to advance it into formal IND-enabling studies, which depends entirely on the company securing additional financing. The company's near-term binary events (January 2027 tafenoquine babesiosis readout) are unrelated to castanospermine.
Price Chart
Executive Summary
Castanospermine is a naturally occurring iminosugar from the Australian chestnut tree that inhibits alpha-glucosidase enzymes, disrupting viral glycoprotein processing. 60 Degrees Pharmaceuticals (NASDAQ: SXTP) has secured an exclusive option from Florida State University to license castanospermine for four tick-borne disease indications (Powassan virus, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease). However, the program is at preclinical/nonclinical stage only, with no clinical trials initiated. The company is a micro-cap with severe cash constraints (~$1M at Q2 2026 end, going-concern risk flagged) and the stock trades near $0.73, down from a $8.62 52-week high. Castanospermine is a very early, high-risk pipeline addition at a cash-strapped developer whose near-term survival depends on its tafenoquine franchise, not this compound.
How It Works
Castanospermine is a natural compound from the Australian chestnut tree that blocks a key enzyme (alpha-glucosidase) that viruses need to properly build their outer proteins. By gumming up this enzyme, the drug prevents viruses from maturing and spreading to new cells. It is a host-targeting antiviral, meaning it acts on human cells rather than on the virus directly, which could make it harder for viruses to develop resistance.
Trial Status
Castanospermine has demonstrated antiviral and immunomodulatory activity in preclinical studies. Its prodrug celgosivir was previously tested in Phase 2 clinical trials for hepatitis C and dengue by other developers. 60 Degrees Pharmaceuticals has not initiated any clinical trials for castanospermine itself. The company recently announced a sponsored research agreement with the University of Southern Mississippi (October 28, 2026) to evaluate castanospermine in nonclinical models of alpha-gal syndrome.
The Two-Sided Case
Upcoming Catalysts
- No hard, dated catalyst for castanospermine in the next ~12 months.
- The company's main near-term binary event is the unblinding and reporting of Phase 2 babesiosis data for tafenoquine in January 2027, which is unrelated to castanospermine.
- Any decision to advance castanospermine into IND-enabling studies would depend on the company's ability to raise additional capital.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sixty Degrees Pharmaceuticals Press Release SXTP ·Originating report